ArticleRheumatology international2013
Inclusion body myositis associated with Sjögren's syndrome.
Article in Rheumatology international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology (Oxford, England) · 2025Guideline
- Case Report: Progressive interstitial lung disease secondary to Sjögren's disease in a patient with inclusion body myositis complicated by dysphagia-a multidisciplinary approach and therapeutic challenges.Frontiers in medicine · 2025Article
- The Plasma Cell Infiltrate Populating the Muscle Tissue of Patients with Inclusion Body Myositis Features Distinct B Cell Receptor Repertoire Properties.ImmunoHorizons · 2023Article
- Muscle architecture in patients with primary Sjögren syndrome.Archives of rheumatology · 2023Article
- A comprehensive two-sample Mendelian randomization analysis of trigeminal neuralgia and modifiable risk factors.Frontiers in neurology · 2023Article
- Pathogenesis and treatment of Sjogren's syndrome: Review and update.Frontiers in immunology · 2023Review
- Potential common molecular mechanisms between Sjögren syndrome and inclusion body myositis: a bioinformatic analysis andFrontiers in immunology · 2023Article
- Sporadic inclusion body myositis and primary Sjogren's syndrome: an overlooked diagnosis.Clinical rheumatology · 2021Article
- Secondary Causes of Myositis.Current treatment options in neurology · 2020Review
- Immunohistochemical and ultrastructural analysis of sporadic inclusion body myositis: a case series.Rheumatology international · 2019Article
- A Patient with Sjogren's Syndrome and Subsequent Diagnosis of Inclusion Body Myositis and Light-Chain Amyloidosis.Journal of general internal medicine · 2019Article
- Inclusion body myositis: clinical features and pathogenesis.Nature reviews. Rheumatology · 2019Review
- Sjögren Syndrome Associated with Inflammatory Muscle Diseases.Mediterranean journal of rheumatology · 2018Article
- Neurological manifestations of primary Sjögren's syndrome.Reumatologia · 2018Review
- Secondary myopathy due to systemic diseases.Acta neurologica Scandinavica · 2016Review
- Efficacy of immunosuppressive treatment in a systemic lupus erythematosus patient presenting with inclusion body myositis.BMJ case reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inclusion body myositis (IBM) belongs to the group of idiopathic inflammatory myopathies. It is a poorly understood disease, which affects skeletal muscles. IBM usually occurs as an isolated condition, but in some cases, it may be associated with another autoimmune disorder, Sjögren's syndrome. We report a case of a 47-year-old woman with headaches, symptoms of trigeminal neuralgia, progressive weakness in muscles of the upper and lower extremities and symptoms of dry eyes and mouth. On admission, creatine kinase level was increased to 6,956 IU/mL and lactate dehydrogenase (LDH) to 1,011 U/L in the serum. The increase in inflammatory factor (CRP, ESR) levels was not found. The diagnosis of inclusion body myositis associated with Sjögren's syndrome was established on the basis of clinical picture and diagnostic tests. In this therapy, methotrexate and methylprednisolone were administered. The considerable improved muscle strength in the upper and lower extremities, improved speech and swallowing, disappearance of headache and reduction in CPK and LDH levels were found 8 months after establishing the diagnosis. Treatment with methotrexate and methylprednisolone improved the clinical symptoms and quality of life of this patient and may offer a therapeutic option for some patients with IBM and concomitant Sjögren's syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.